Abbott Laboratories 향후 성장

Future 기준 점검 0/6

Abbott Laboratories 의 수익은 연간 8.9% 감소할 것으로 예상되는 반면, 연간 수익은 7% 로 증가할 것으로 예상됩니다. EPS는 연간 9.2% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 19.1% 로 예상됩니다.

핵심 정보

-8.9%

이익 성장률

-9.18%

EPS 성장률

Medical Equipment 이익 성장	12.7%
매출 성장률	7.0%
향후 자기자본이익률	19.10%
애널리스트 커버리지	Good
마지막 업데이트	01 Oct 2025

최근 향후 성장 업데이트

Recent updates

Investors Shouldn't Be Too Comfortable With Abbott Laboratories' (NYSE:ABT) Earnings

Feb 28

Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price

Feb 17

Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?

Feb 05

Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)

Jan 23

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Jan 13

Abbott Laboratories Q4 2024 Earnings Preview

Jan 08

Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline

Dec 21

Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)

Dec 01

Abbott Laboratories: Investors Should Wait For A Pullback

Nov 25

Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Oct 31

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Oct 21

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Oct 14

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Oct 11

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

Abbott Laboratories: Why I Agree With Wall Street On This One

Jun 04

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

May 18

이익 및 매출 성장 예측

NYSE:ABT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	51,661	9,023	8,857	11,685	22
12/31/2026	48,156	8,057	8,463	10,604	27
12/31/2025	44,676	7,079	7,592	10,246	27
6/30/2025	43,109	13,928	6,775	9,037	N/A
3/31/2025	42,344	13,451	6,657	8,950	N/A
12/31/2024	41,950	13,351	6,351	8,558	N/A
9/30/2024	41,217	5,755	6,486	8,728	N/A
6/30/2024	40,725	5,546	5,654	7,900	N/A
3/31/2024	40,326	5,608	4,923	7,143	N/A
12/31/2023	40,109	5,701	5,059	7,261	N/A
9/30/2023	39,959	5,142	4,492	6,549	N/A
6/30/2023	40,226	5,140	5,488	7,452	N/A
3/31/2023	41,505	5,785	6,823	8,659	N/A
12/31/2022	43,653	6,905	7,804	9,581	N/A
9/30/2022	45,030	7,857	8,541	10,322	N/A
6/30/2022	45,548	8,520	8,468	10,243	N/A
3/31/2022	44,514	7,695	8,152	9,961	N/A
12/31/2021	43,075	7,042	8,648	10,533	N/A
9/30/2021	42,308	7,208	9,314	11,264	N/A
6/30/2021	40,233	6,343	8,644	10,629	N/A
3/31/2021	37,338	5,693	7,609	9,823	N/A
12/31/2020	34,608	4,449	5,724	7,901	N/A
9/30/2020	32,221	3,346	4,587	6,519	N/A
6/30/2020	31,444	3,073	4,564	6,401	N/A
3/31/2020	32,095	3,539	4,476	6,139	N/A
12/31/2019	31,904	3,666	4,498	6,136	N/A
9/30/2019	31,355	3,272	3,814	5,485	N/A
6/30/2019	30,935	2,867	4,096	5,720	N/A
3/31/2019	30,723	2,582	N/A	5,904	N/A
12/31/2018	30,578	2,319	N/A	6,300	N/A
9/30/2018	30,402	802	N/A	6,175	N/A
6/30/2018	29,575	812	N/A	5,997	N/A
3/31/2018	28,445	365	N/A	6,104	N/A
12/31/2017	27,390	344	N/A	5,570	N/A
9/30/2017	25,134	1,971	N/A	5,100	N/A
6/30/2017	23,607	1,055	N/A	4,312	N/A
3/31/2017	22,303	1,384	N/A	3,870	N/A
12/31/2016	20,853	1,056	N/A	3,203	N/A
9/30/2016	20,708	989	N/A	2,861	N/A
6/30/2016	20,556	1,939	N/A	2,839	N/A
3/31/2016	20,393	2,124	N/A	2,871	N/A
12/31/2015	20,405	2,586	N/A	2,966	N/A
9/30/2015	20,573	2,523	N/A	3,376	N/A
6/30/2015	20,502	2,365	N/A	3,382	N/A
3/31/2015	20,389	2,004	N/A	3,341	N/A
12/31/2014	20,247	1,710	N/A	3,675	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ABT 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -8.9%).

수익 vs 시장: ABT 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -8.9%).

고성장 수익: ABT 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: ABT 의 수익(연간 7%)이 US 시장(연간 9.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: ABT 의 수익(연간 7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ABT의 자본 수익률은 3년 후 19.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/03 04:31
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Abbott Laboratories는 66명의 분석가가 다루고 있습니다. 이 중 27명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Stephan Gasteyger	Atlantic Equities LLP
Ishan Majumdar	Baptista Research

Abbott Laboratories 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Abbott Laboratories Provides Earnings Guidance for 2025

Abbott Laboratories Reaffirms Earnings Guidance for the Full Year 2025

Abbott Laboratories Provides Earnings Guidance for the Full Year 2025

Abbott Laboratories Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Recent updates

Insufficient new directors

Abbott's Dissolving Stent Receives Health Canada Approval for Treating Blocked Arteries Below-The-Knee

Abbott Laboratories to Report Q3, 2025 Results on Oct 15, 2025

Second quarter dividend of US$0.59 announced

Abbott Declares 407th Consecutive Quarterly Dividend, Payable on November 17, 2025

There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

Abbott Reportedly in Talks with Synlait Milk About Buying One of its Manufacturing Facilities in New Zealand

Abbott Laboratories Q2 Earnings: Dividends Don't Lie

New major risk - Revenue and earnings growth

Second quarter 2025 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for 2025

Abbott's Latest-Generation Freestyle Libre 3 Plus Glucose Sensor Technology Launches in Canada

Upcoming dividend of US$0.59 per share

Abbott Laboratories to Report Q2, 2025 Results on Jul 17, 2025

First quarter dividend of US$0.59 announced

Abbott Declares 406Th Consecutive Quarterly Dividend, Payable on August 15, 2025

Abbott Receives FDA Approval for Tendyne™?, First-Of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery

Abbott Announces Results from Its Reflect Real-World Studies That Show the Use of Freestyle Libre®? Continuous Glucose Monitoring (Cgm) Technology

Abbott Laboratories Announces Retirement of Hubert L. Allen as Executive Vice President, General Counsel and Secretary

Abbott Highlights New AVEIR Data, Initiates Trial for the Company's Conduction System Pacing Technology

Abbott Laboratories Reaffirms Earnings Guidance for the Full Year 2025

First quarter 2025 earnings: EPS misses analyst expectations

Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices

Upcoming dividend of US$0.59 per share

Abbott Announces New Late-Breaking Data Reinforce Benefits of Abbott's TriClip for People with Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2025 Results on Apr 16, 2025

Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease

Abbott Laboratories, Annual General Meeting, Apr 25, 2025

Abbott Laboratories Basking In A Sharp Turn In Sentiment

Insider exercised options and sold US$4.8m worth of stock

Investors Shouldn't Be Too Comfortable With Abbott Laboratories' (NYSE:ABT) Earnings

Fourth quarter dividend of US$0.59 announced

Full year 2024 earnings: EPS exceeds analyst expectations

Abbott Declares Quarterly Common Dividend, Payable on May 15, 2025

Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price

Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?

Executive VP exercised options and sold US$17m worth of stock

New major risk - Revenue and earnings growth

Full year 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2025

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Abbott Laboratories Q4 2024 Earnings Preview

Upcoming dividend of US$0.59 per share

Abbott Laboratories to Report Q4, 2024 Results on Jan 22, 2025

Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline

Third quarter dividend increased to US$0.59

Abbott's FreeStyle Libre®? 2 Now Reimbursed for Children and Adults Living with Diabetes in Alberta

Abbott Declares Quarterly Common Dividend, Payable February 14, 2025

Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)

Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis

Abbott Laboratories: Investors Should Wait For A Pullback

Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

Executive VP notifies of intention to sell stock

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Third quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Upcoming dividend of US$0.55 per share

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Chairman of the Board notifies of intention to sell stock

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Abbott Laboratories: Driving Value By Scaling Innovations

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors